Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Pediatric Vaccine Market Forecast: Value Set To Climb From $65.01 Billion To $107.8 Billion
The pediatric vaccine market size has experienced rapid expansion in recent years. This market is projected to increase from $57.51 billion in 2025 to $65.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. Historically, this growth is attributable to factors such as the increasing occurrence of preventable childhood illnesses, government-sponsored immunization initiatives, innovations in vaccine adjuvants, heightened understanding of pediatric health, and the expansion of cold chain infrastructure.
The pediatric vaccine market is poised for significant expansion in the coming years. It is forecasted to reach $107.8 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. The impetus for this growth during the projection period stems from advancements in mRNA and DNA vaccines, increased investment in pediatric vaccine research and development, the integration of digital health monitoring, the broadening of healthcare infrastructure in emerging markets, and strategic alliances between biotech companies and global health organizations. Noteworthy trends anticipated in the forecast period include a sharpened focus on vaccine availability in low-income areas, the increasing adoption of combination vaccines, the enlargement of school-based immunization programs, the creation of new pediatric vaccines for rare conditions, and a rise in public-private partnerships dedicated to vaccine research.
Get A Free Sample Report With In-Depth Market Insights:
Pediatric Vaccine Market Industry Drivers: What’s Behind The Revenue Growth?
The escalating occurrence of chronic ailments like tuberculosis, diphtheria, and pneumonia among individuals aged 15 and under is set to boost the pediatric vaccines market. Children and adolescents living with chronic conditions face a heightened risk of severe outcomes and complications from infectious diseases. As an illustration, in June 2024, the National Health Service, a UK government body, reported that 3,615,330 individuals registered with a general practitioner (GP) received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023. This figure represents an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the increasing prevalence of chronic diseases is propelling the expansion of the pediatric vaccine market.
Pediatric Vaccine Market Segment Trends And Revenue Contributors
The pediatric vaccine market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies
3) By Application: Infectious Disease, Allergy, Cancer
Subsegments:
1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines
2) By Multivalent: Combination Vaccines, Polyvalent Vaccines
#Pediatric Vaccine Market Growth Trends: What’s Shaping The Future Outlook?
Companies operating within the pediatric vaccine market are concentrating on securing product approvals to better satisfy the demands of their current consumers. ABRYSVO is an FDA-authorized vaccine intended for use in pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in children up to 6 months of age. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, announced the U.S. FDA approval of Pfizer’s ABRYSVO vaccine for the avoidance of Respiratory Syncytial Virus (RSV) in Infants through the active immunization of pregnant women 32-36 weeks gestational age. This constitutes the first and only maternal vaccination approved in the United States designed to help protect newborns against lower respiratory tract illness (LRTD) and severe LRTD caused by RSV from birth to six months of age.
Pediatric Vaccine Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the pediatric vaccine market are Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Sinovac Biotech Ltd, Zydus Cadila, Indian Immunologicals Limited, Panacea Biotec, Takeda Pharmaceutical Company, Daiichi Sankyo, CSL Limited, Sinopharm, Walvax Biotechnology, Fosun Pharma, MCM Vaccine Company, Seqirus, Johnson & Johnson, Connaught Laboratories Inc., Wyeth-Ayerst, Ataulfo de Paiva Foundation, Bio-Manguinhos – Institute of Technology on Immunobiologicals, Butantan Institute, Ezequiel Dias Foundation (FUNED), Sinergium
View The Full Pediatric Vaccine Market Report:
Pediatric Vaccine Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the pediatric vaccine market in 2025. Middle East is expected to be the largest growing region in the global pediatric vaccine market share during the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
